SG10201810404XA - Combination comprising a glucocorticoid and edo-s101 - Google Patents

Combination comprising a glucocorticoid and edo-s101

Info

Publication number
SG10201810404XA
SG10201810404XA SG10201810404XA SG10201810404XA SG10201810404XA SG 10201810404X A SG10201810404X A SG 10201810404XA SG 10201810404X A SG10201810404X A SG 10201810404XA SG 10201810404X A SG10201810404X A SG 10201810404XA SG 10201810404X A SG10201810404X A SG 10201810404XA
Authority
SG
Singapore
Prior art keywords
combination
glucocorticoid
edo
kit
composition
Prior art date
Application number
SG10201810404XA
Inventor
Thomas Jorg Mehrling
Enrique Maria Ocio
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SG10201810404XA publication Critical patent/SG10201810404XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

COMBINATION COMPRISING A GLUCOCORTICOID AND EDO-S101 The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: ( I ) to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit. Figure 2 N N N Cl Cl HN OH O
SG10201810404XA 2014-05-28 2015-05-26 Combination comprising a glucocorticoid and edo-s101 SG10201810404XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1409485.8A GB201409485D0 (en) 2014-05-28 2014-05-28 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
SG10201810404XA true SG10201810404XA (en) 2018-12-28

Family

ID=51177587

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201609362YA SG11201609362YA (en) 2014-05-28 2015-05-26 Combination comprising a glucocorticoid and edo-s101
SG10201810404XA SG10201810404XA (en) 2014-05-28 2015-05-26 Combination comprising a glucocorticoid and edo-s101

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201609362YA SG11201609362YA (en) 2014-05-28 2015-05-26 Combination comprising a glucocorticoid and edo-s101

Country Status (19)

Country Link
US (3) US10744120B2 (en)
EP (1) EP3148584B1 (en)
JP (2) JP2017518292A (en)
KR (1) KR20170008846A (en)
CN (1) CN106488776B (en)
AU (1) AU2015266053B2 (en)
BR (1) BR112016027043B1 (en)
CA (1) CA2950340C (en)
DK (1) DK3148584T3 (en)
EA (1) EA038323B1 (en)
ES (1) ES2885429T3 (en)
GB (1) GB201409485D0 (en)
IL (1) IL249230A0 (en)
MX (1) MX2016015437A (en)
PH (1) PH12016502352A1 (en)
SG (2) SG11201609362YA (en)
TW (1) TWI731837B (en)
UA (1) UA121392C2 (en)
WO (1) WO2015181157A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092790A1 (en) 2012-02-01 2015-05-06 Euro Celtique Sa BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
KR20210105380A (en) * 2018-12-18 2021-08-26 먼디파머 인터내셔널 코포레이션 리미티드 Compounds for treating multiple myeloma

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (en) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Process for the direct extraction of metallic lead
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
KR0166088B1 (en) 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
AU750207B2 (en) 1997-06-13 2002-07-11 Cydex Pharmaceuticals, Inc. Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
WO2002004009A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
DE60138658D1 (en) 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbamic acid derivatives containing an amide group for the treatment of malaria
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
CN1764648A (en) 2003-01-13 2006-04-26 安斯泰来制药有限公司 hydroxamid acid derivatives as histone deacetylase (HDAC) inhibitors
JP4790594B2 (en) 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Hydroxamic acid compounds containing bicyclic heteroaryl groups as HDAC inhibitors
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
EP1745022B1 (en) 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
ZA200710313B (en) 2005-05-13 2009-05-27 Topotarget Uk Ltd Pharmaceutical formulations of HDAC inhibitors
KR20110098009A (en) 2006-10-20 2011-08-31 이코스 코포레이션 Compositions of chk1 inhibitors and cyclodextrin
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
CL2007003331A1 (en) 2006-11-20 2008-07-04 Cephalon Inc METHOD TO TREAT CANCER THROUGH THE ADMINISTRATION OF A BENZO RADIOSENSIBILIZING AGENT [A] TRINDEN-4,6-DIONA; PHARMACEUTICAL COMPOSITION UNDERSTANDING THIS AGENT.
CN101084876A (en) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 Anti-cancer composition containing bendamustine
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
JP5773874B2 (en) 2008-10-08 2015-09-02 セファロン、インク． Method for preparing bendamustine
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
PL2389375T3 (en) * 2009-01-23 2015-11-30 Euro Celtique Sa Hydroxamic acid derivatives
EP2792369B1 (en) 2009-02-25 2018-04-18 Softkemo Pharma Corp. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (en) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-(hetero)aryl-N-hydroxyl hexanamide/heptamide compounds and method for preparing same
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011127948A1 (en) 2010-04-16 2011-10-20 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
JO3659B1 (en) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh Oral dosage forms of bendamustine and therapeutic use thereof
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
CN102993102B (en) 2011-09-16 2016-08-24 杭州民生药业有限公司 The synthetic method of [1-methyl-2-(hydroxamic acid base in 7 '-heptan)-5-N, N-bis-(2 '-chloroethyl)]-1H-benzimidazole
AP3656A (en) * 2011-09-18 2016-04-04 Euro Celtique Sa Pharmaceutical compositions
TW201326162A (en) 2011-09-28 2013-07-01 Euro Celtique Sa Nitrogen mustard derivatives
AR092790A1 (en) 2012-02-01 2015-05-06 Euro Celtique Sa BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2015356779A1 (en) 2014-12-05 2017-07-13 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma
CN106580971B (en) 2015-10-20 2019-11-12 杭州梯诺医药科技有限公司 A kind of pharmaceutical composition and preparation method thereof
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma

Also Published As

Publication number Publication date
TWI731837B (en) 2021-07-01
EP3148584A1 (en) 2017-04-05
JP2017518292A (en) 2017-07-06
AU2015266053A1 (en) 2016-11-17
CA2950340C (en) 2023-10-17
US20170296513A1 (en) 2017-10-19
EA038323B1 (en) 2021-08-10
GB201409485D0 (en) 2014-07-09
DK3148584T3 (en) 2021-08-30
BR112016027043A8 (en) 2021-07-20
UA121392C2 (en) 2020-05-25
AU2015266053B2 (en) 2020-07-02
CN106488776A (en) 2017-03-08
CA2950340A1 (en) 2015-12-03
BR112016027043A2 (en) 2017-08-15
SG11201609362YA (en) 2016-12-29
CN106488776B (en) 2021-01-22
US10744120B2 (en) 2020-08-18
US11541038B2 (en) 2023-01-03
EP3148584B1 (en) 2021-05-26
KR20170008846A (en) 2017-01-24
EA201692481A1 (en) 2017-04-28
MX2016015437A (en) 2017-06-23
TW201613577A (en) 2016-04-16
PH12016502352A1 (en) 2017-02-13
WO2015181157A1 (en) 2015-12-03
US20210059989A1 (en) 2021-03-04
US20230285363A1 (en) 2023-09-14
JP2021046446A (en) 2021-03-25
IL249230A0 (en) 2017-02-28
BR112016027043B1 (en) 2023-01-31
ES2885429T3 (en) 2021-12-13

Similar Documents

Publication Publication Date Title
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX2020007485A (en) Antiproliferative compounds and methods of use thereof.
TW201613578A (en) Pharmaceutical combinations
PH12016501750A1 (en) Human plasma kallikrein inhibitors
NZ726366A (en) Syk inhibitors
MX368903B (en) THERAPEUTIC COMPOUNDS and USES THEREOF.
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2018009173A (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH).
MX2018004664A (en) Ep4 antagonists.
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2016016388A (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds.
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2021014120A (en) Treatment of androgen deprivation therapy associated symptoms.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2015017124A (en) Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy.